Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,123 across all filing types
Latest filing 2025-08-26 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Announcement of Interim Results' for PegBio Co., Ltd. for the six months ended June 30, 2025. It contains unaudited consolidated financial statements, financial highlights, and a detailed Management Discussion & Analysis (MDA) section. Since it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-26 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 1% confidence The document is a ‘Positive Profit Alert’ announcing preliminary, unaudited profit expectations for the half-year ended 30 June 2025. It is a market announcement of key interim financial highlights rather than a full interim report or formal audited results. This aligns with an Earnings Release (ER) category, which covers initial announcements of quarterly/periodical financial results. H1 2025
2025-08-20 English
DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITIONS OF NOTES
Capital/Financing Update Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement by CMBC Capital Holdings Limited detailing the acquisition of US dollar‐denominated notes (debt instruments) in the over‐the‐counter market. It describes principal terms, Listing Rules implications for discloseable transactions under Chapter 14, funding sources, and reasons/benefits for the acquisition. This is not a full financial report, earnings release, board change, or share issuance, but rather a financing transaction announcement (the company acquiring debt securities). Therefore, it falls under Capital/Financing Update (CAP).
2025-08-20 English
DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF BONDS
Capital/Financing Update Classification · 1% confidence The document is an official listing-rule announcement by CMBC Capital Holdings Limited concerning a discloseable transaction under Chapter 14 of the HK Listing Rules. It details the company’s acquisition of US$15 million bonds in the OTC market, describes transaction terms, funding, and listing-rule implications. This is a financing activity announcement rather than a management change, earnings release, or full report. Therefore, it is best classified under Capital/Financing Update (CAP).
2025-08-20 English
DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSALS OF CONVERTIBLE SECURITIES
Capital/Financing Update Classification · 1% confidence The document is an official announcement under the Hong Kong Listing Rules by CMBC Capital Holdings Limited, detailing a “disclosable transaction” involving the disposal of US$10 million in aggregate principal amount of convertible securities by its subsidiary. It describes the transaction terms, listing rules implications, financial effects, and other transaction-specific details. This is not an earnings release, board change, share issue, or AGM material. Instead, it reports a significant financing/capital transaction (the sale of convertible securities to raise cash), which aligns with the “Capital/Financing Update” category (CAP).
2025-08-19 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement notifying investors of the date of a Board meeting to consider and approve the company’s interim results and draft announcement. It does not contain the actual results themselves but rather sets the timetable for their publication. Under our taxonomy, this is an announcement regarding the timing and publication of a report rather than the report itself. Therefore, it falls under Report Publication Announcement (RPA).
2025-08-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.